問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital-Taipei

未分科

List

275Cases

2017-04-01 - 2019-10-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    GDC-0853

Participate Sites
8Sites

Terminated6Sites

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-03-01 - 2019-09-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically confirmed Duodenal Ulcer Subjects with or without Helicobacter pylori infection

  • Condition/Disease

    Duodenal Ulcer

  • Test Drug

    TAK-438

Participate Sites
6Sites

Terminated5Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-01-01 - 2020-10-31

Phase III

A Multicenter, Open-label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Olokizumab

Participate Sites
5Sites

Recruiting2Sites

Terminated1Sites

Study ended1Sites

2017-03-01 - 2020-06-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection

  • Condition/Disease

    Gastric Ulcer

  • Test Drug

    TAK-438

Participate Sites
6Sites

Recruiting5Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-07-01 - 2019-10-29

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug- Experienced Patients with Active Psoriatic Arthritis

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Ixekizumab(LY2439821)

Participate Sites
8Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

藍忠亮
China Medical University Hospital-Taipei

未分科

2015-08-17 - 2017-11-30

Phase III

A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily administration of TAK-438 20 mg compared to Lansoprazole 30 mg in the Treatment of Subjects with Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

侯明志
Taipei Veterans General Hospital

Digestive System Department

2015-08-17 - 2018-02-28

Phase III

A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2016-09-01 - 2019-01-31

Phase III

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Olokizumab

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

黃春明
China Medical University Hospital

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

  • Condition/Disease

    Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

  • Test Drug

    avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙
Linkou Chang Gung Medical Foundation

白禮源
China Medical University Hospital-Taipei

未分科

2016-02-01 - 2019-01-16

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated3Sites

1 19 20 21 22 23 28
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB